Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Amir Razaghizad,Emily Oulousian,Varinder Kaur Randhawa,João Pedro Ferreira,James M. Brophy,Stephen J. Greene,Julian Guida,G. Michael Felker,Marat Fudim,Michael Tsoukas,Tricia M. Peters,Thomas A. Mavrakanas,Nadia Giannetti,Justin Ezekowitz,Abhinav Sharma
DOI: https://doi.org/10.1161/JAHA.121.024833
2022-05-17
Abstract:Background Clinical prediction models have been developed for hospitalization for heart failure in type 2 diabetes. However, a systematic evaluation of these models' performance, applicability, and clinical impact is absent. Methods and Results We searched Embase, MEDLINE, Web of Science, Google Scholar, and Tufts' clinical prediction registry through February 2021. Studies needed to report the development, validation, clinical impact, or update of a prediction model for hospitalization for heart failure in type 2 diabetes with measures of model performance and sufficient information for clinical use. Model assessment was done with the Prediction Model Risk of Bias Assessment Tool, and meta‐analyses of model discrimination were performed. We included 15 model development and 3 external validation studies with data from 999 167 people with type 2 diabetes. Of the 15 models, 6 had undergone external validation and only 1 had low concern for risk of bias and applicability (Risk Equations for Complications of Type 2 Diabetes). Seven models were presented in a clinically useful manner (eg, risk score, online calculator) and 2 models were classified as the most suitable for clinical use based on study design, external validity, and point‐of‐care usability. These were Risk Equations for Complications of Type 2 Diabetes (meta‐analyzed c‐statistic, 0.76) and the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (meta‐analyzed c‐statistic, 0.78), which was the simplest model with only 5 variables. No studies reported clinical impact. Conclusions Most prediction models for hospitalization for heart failure in patients with type 2 diabetes have potential concerns with risk of bias or applicability, and uncertain external validity and clinical impact. Future research is needed to address these knowledge gaps. Nonstandard Abbreviations and Acronyms ACCORD Action to Control Cardiovascular Risk in Diabetes trial HHF hospitalization for heart failure PROBAST Prediction Model Risk of Bias Assessment Tool RECODe Risk Equations for Complications of Type 2 Diabetes TRS‐HF DM Thrombolysis in Myocardial Infarction Risk Score for HF in Diabetes WATCH‐DM (Weight [BMI], Age, Hypertension, Creatinine, HDL‐C, Diabetes Control [fasting plasma glucose], QRS Duration, MI, and CABG) risk score Clinical Perspective What Is New? Available evidence suggests that several widely available clinical risk tools can robustly prognosticate the risk of heart failure hospitalization in people with type 2 diabetes and identify those who may benefit most from novel guideline‐directed medical therapies. The effect of most clinical prediction models on clinical outcomes, patient care, provider behaviors has largely been under investigated, as a result, health, economic, and clinical investigations of these tools are warranted. What Are the Clinical Implications? Given that several clinical prediction models have demonstrated robust prognostic accuracy, their implementation in clinical settings might facilitate the identification of high‐risk individuals with type 2 diabetes who may benefit most from guideline‐directed therapies such as sodium‐glucose co‐transporter 2 inhibitors. Type 2 diabetes (T2D) contributes to >1.5 million annual deaths worldwide. 1 This high rate of mortality can be partly attributed to the metabolic alterations that precipitate diabetic cardiomyopathy and its attendant complications. 2 Correspondingly, the development of heart failure (HF) has emerged as one of the most common and important manifestations of cardiovascular disease in individuals with diabetes. 3 The concern over HF initially stemmed from safety troubles with certain antidiabetic treatments (eg, thiazolidinediones), and the fact that hospitalizations for heart failure (HHF) portend a poor prognosis. 4 , 5 Thus, the use of prediction models for identifying patients with diabetes at particularly high risk for developing HF -Abstract Truncated-